HapMap, pharmacogenomics, and the goal of personalized prescribing

British Journal of Clinical Pharmacology

Volumn 61, Issue 6, 2006, Pages 783-786

  O'Shaughnessy, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HapMp; Personalized prescribing; Pharmacogenomics

Indexed keywords

DNA POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG DESIGN; GENETIC VARIATION; GENOME, HUMAN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 33646944372     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02683.x     Document Type: Review

References (14)

1. Vogel F. Moderne problem der humangenetik. Ergeb Inn Med U Kinnderheilk 1959 12: 52 125.
2. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. International HapMap Consortium. A haplotype map of the human genome. Nature 2005 437 7063 1299 320.
3. International HapMap Project. http://www.hapmap.org Last accessed 2 April 2006.
4. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001 291 5507 1304 51.
5. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001 409 6822 860 921.
6. National Center for Biotechnology Information. Single Nucleotide Polymorphism. http://www.ncbi.nlm.nih.gov/SNP Last accessed 2 April 2006.
7. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005 94: 773 9.
8. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Aacad Sci USA 2005 102: 4134 9.
9. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, Lelouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC. A marker for Stevens - Johnson syndrome...: ethnicity matters. Pharmacogenomics J 2006 [Epub] DOI: 10.1038/sj.tpj.6500356.
10. Cheok MH, Lugthart S, Evans WE. Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006 46: 317 53.
11. Simon R, Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 2006 [Epub] DOI: 10.1038/sj.tpj.6500349.
12. Murphy GM Jr., Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004 61: 1163 9.
13. Lesko LJ, Salerno RA, Spear BB, Anderson DC, Anderson T, Brazell C, Collins J, Dorner A, Essayan D, Gomez-Mancilla B, Hackett J, Huang SM, Ide S, Killinger J, Leighton J, Mansfield E, Meyer R, Ryan SG, Schmith V, Shaw P, Sistare F, Watson M, Worobec A. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 2003 43: 342 58.
14. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat Rev Drug Discov 2005 4: 639 47.